ACP
UTHR icon

Acuta Capital Partners’s United Therapeutics UTHR Stock Holding History

Acuta Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-25,000
Closed -$2.81M – 74
2018
Q1 		$2.81M Buy
+25,000
New +$3.18M 0.46% 32

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acuta Capital Partners's UTHR Position: Q1 2026 in Review

Acuta Capital Partners reduced its United Therapeutics (UTHR) stake by 3.1% in Q1 2026, selling an estimated $35.9K and leaving 2,224 shares worth $1.32M. The position accounts for 0.93% of the portfolio, ranked #21.

Acuta Capital Partners first reported a position in UTHR in Q3 2021 and has held it in 8 quarters since. The position peaked at $9.18M in Q4 2022. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Acuta Capital Partners held 2,224 shares of United Therapeutics worth $1.32M as of Q1 2026.
  • Acuta Capital Partners sold 72 United Therapeutics shares in Q1 2026, an estimated $35.9K.
  • United Therapeutics made up 0.93% of Acuta Capital Partners's portfolio in Q1 2026, its #21 holding.
  • Acuta Capital Partners first reported a position in United Therapeutics in Q3 2021 and has held it in 8 quarters since.
  • Acuta Capital Partners's United Therapeutics position peaked at $9.18M in Q4 2022.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.